timothy sykes logo
ELAN Stock Holds Gains As Traders Watch Key Levels Thumbnail
G Google News

ELAN Stock Holds Gains As Traders Watch Key Levels

JACK KELLOGG•UPDATED MAY. 8, 2026, 4:38 PM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

Elanco Animal Health Incorporated stocks have been trading down by -5.27 percent following bearish analyst revisions and weaker growth outlooks.

Candlestick Chart

Weekly Update May 04 – May 08, 2026: On Friday, May 08, 2026 Elanco Animal Health Incorporated stock [NYSE: ELAN] is trending down by -5.27%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – neutral

Elanco (ELAN) holds a solid but subscale position in global animal health, with strong 55% gross margin but still-transitioning profitability. LTM EBIT margin of 0.9% and negative net margin (~-5%) underline incomplete integration and cost-takeout. Revenue growth is mid‑single digit (5‑year CAGR ~7.5%) but conversion to cash is weak: price-to-free-cash ~71x and price-to-cash-flow ~30x are rich versus lackluster ROE (-5%) and ROA (-2%). Balance sheet is sound: net leverage moderate (debt/equity 0.61, interest coverage 15x, current ratio 2.2).

Technically, ELAN shows a sharp spike then rejection: after trading tightly at 22.51–22.99, price jumped to 26.30 intraday (260506) but closed lower at 26.01, then reversed to 23.75 and stabilized at 23.65. That pattern signals a failed breakout and near-term supply overhead around 26. On 5‑minute candles, volume expanded on the push above 26 and again on the reversal, confirming sellers. The actionable level is 23.50: a decisive break below invites a move back toward 22.50.

With no major near-term news, the story is execution and margin normalization relative to animal-health peers (Zoetis, IDEXX) and broader Healthcare/Pharma benchmarks that deliver higher ROIC and cleaner cash generation. Elanco screens as a late-cycle self‑help turnaround rather than a quality compounder. Base case: consolidation between 22 and 26 while management drives cost discipline and working-capital normalization; accumulation zone 22–23, resistance 26, upside target 28 over 12–18 months if EBIT margin clears mid‑single digits sustainably.

Quick Financial Overview

Elanco Animal Health Incorporated delivered quarterly revenue of about $1.37B, with gross profit near $785M, indicating a strong 55% gross margin. Operating income of $103M and net income of $57M show the company is profitable at the operating line, but overall margins remain slim. Net margin is low relative to revenue, which lines up with the negative longer-term profit margin metrics in the key ratios.

On the balance sheet, ELAN carries total assets of roughly $13.22B and equity around $6.5B, for a price-to-book near 2. Leverage is moderate, with long-term debt of about $3.92B and a total debt-to-equity ratio of 0.61. Liquidity looks reasonable, with a current ratio of 2.2 and working capital close to $1.92B, which helps support ongoing restructuring and R&D needs.

Cash flow is more mixed. Operating cash flow in the latest quarter was positive at $13M, but heavy working-capital drag and capital spending pushed free cash flow to about -$38M. Enterprise value is roughly $15.55B, and with annual revenue around $4.72B, ELAN trades at about 2.8x sales and a rich price-to-free-cash multiple, which tells traders the market is already pricing in a smoother earnings path ahead.

More Breaking News

Conclusion

For short-term traders, the ELAN chart is the first filter. Weekly data show a sharp push up to the $26 area followed by a pullback and consolidation around the mid-$23s. That pattern often signals digestion after a momentum move rather than a full trend reversal, as long as price holds above key support. The recent close near $23.65 keeps Elanco Animal Health Incorporated in a constructive zone, but the next move will be defined by how price behaves around $23 and the low $24s.

Intraday, ELAN showed a clear fade from the $24.40–$24.60 range early in the session down toward $23.20–$23.30, then stabilized and bounced modestly into the close. That action sets up a simple trading map: $23.00–$23.20 as intraday support, and $24.20–$24.60 as short-term resistance. Combined with improving but still thin profitability, traders should see this as a name where execution risk remains, but the balance sheet and revenue base give it room to work. This is exactly the kind of situation where disciplined planning and waiting for clean setups matter. As millionaire penny stock trader and teacher Tim Sykes says, “Preparation plus patience leads to big profits.” Applied here, it means doing the homework on key levels and then letting the price action come to you instead of forcing trades in the middle of the range.

For Elanco Animal Health Incorporated, the risk/reward right now is about how long the market is willing to wait for cleaner margins and stronger free cash flow. Range traders can focus on scalping moves between established support and resistance, while swing traders may wait for a confirmed break above recent highs or a decisive rejection at support. As I tell my students, “Your edge in names like ELAN comes from respecting the levels and letting the tape prove the next direction before you size up.”

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading ELAN

Millionaire's
POV on ELAN

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”